Health-care professionals' perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation.

abstract：:Hurler syndrome (MPS1H) is a progressive inborn error of mucopolysaccharide metabolism leading to premature death. Allogeneic hematopoietic cell transplantation (HCT) can achieve stabilization and improve long-term survival. However, large studies have shown that preparative regimen-related toxicity (RRT) and graft fa...

journal_title：Bone marrow transplantation

authors： Grigull L,Beilken A,Schrappe M,Das A,Luecke T,Sander A,Stanulla M,Rehe K,Sauer M,Schmid H,Welte K,Lukacs Z,Gal A,Sykora KW

更新日期：2005-02-01 00:00:00

abstract：:We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3+ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initiall...

journal_title：Bone marrow transplantation

authors： Ozyurek E,Cowan MJ,Koerper MA,Baxter-Lowe LA,Dvorak CC,Horn BN

更新日期：2008-07-01 00:00:00

abstract：:Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy mainly rely upon prognostic factors, and their importance is constantly reassessed. To examine the impact of time from diagnosis to transplant on survival and leukemia-free survival (LFS), w...

journal_title：Bone marrow transplantation

authors： Jourdan E,Maraninchi D,Reiffers J,Gluckman E,Rio B,Jouet JP,Michallet M,Molina L,Archimbaud E,Harousseau JL,Ifrah N,Attal M,Guilhot F,Kuentz M,Guyotat D,Pico JL,Dauriac C,Legros M,Dreyfus F,Bordigoni P,Leblond V,

更新日期：1997-05-01 00:00:00

abstract：:High-dose immunoablative chemotherapy with autologous haematopoietic cell support might be beneficial in the treatment of intractable forms of MS. We mobilised PBPC in 11 patients with secondary progressive MS and finally eight patients were grafted after high-dose BEAM chemotherapy with either in vitro or in vivo T c...

journal_title：Bone marrow transplantation

authors： Kozák T,Havrdová E,Pit'ha J,Gregora E,Pytlík R,Maaloufová J,Marecková H,Kobylka P,Vodvárková S

更新日期：2000-03-01 00:00:00

abstract：:Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

journal_title：Bone marrow transplantation

authors： Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

更新日期：1998-10-01 00:00:00

abstract：:Patterns of C-reactive protein (CRP) release were derived from frequent CRP measurements in a cohort of 66 consecutive patients receiving allogeneic bone marrow transplants (BMT) in our unit. Based on a retrospective study of clinical events occurring within the first 40 days after BMT, patients with major transplant-...

journal_title：Bone marrow transplantation

authors： Schots R,Kaufman L,Van Riet I,Lacor P,Trullemans F,De Waele M,Van Camp B

更新日期：1998-07-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Serological, cellular and DNA-RFLP (restriction fragment length polymorphism) methods of determining HLA compatibility between 10 leukaemic patients and potential related bone marrow donors were systematically compared. DR beta/DQ alpha/DQ beta/DNA-RFLP typing of these families gave results in agreement with those obt...

journal_title：Bone marrow transplantation

authors： Howell WM,Evans PR,Spellerberg MB,Wilson PJ,Smith JL

更新日期：1989-01-01 00:00:00

abstract：:The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

journal_title：Bone marrow transplantation

authors： Sweetenham JW

更新日期：2001-11-01 00:00:00

abstract：:The purpose of this study was to evaluate pre-transplant T-cell status in autologous hematopoietic progenitor-cell transplantation (HPCT) recipients. Between 1999 and 2002 we prospectively enrolled 85 autologous HPCT recipients with solid tumors (N = 50) or hematological malignancies (n = 35). Patient diagnoses includ...

journal_title：Bone marrow transplantation

authors： Rosinski SL,McNiece IK,Shpall EJ,Clough N,Russell P,Blunk B,Nieto Y

更新日期：2005-09-01 00:00:00

abstract：:Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) r...

journal_title：Bone marrow transplantation

authors： Roghmann M,Ball K,Erdman D,Lovchik J,Anderson LJ,Edelman R

更新日期：2003-12-01 00:00:00

abstract：:The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34(+) stem cells of healthy donors (HD). In 2008, the G-CSF biosimilar XM02 (Ratiograstim, Tevagrastim and Biograstim) was approved by the European Medicines Agency (EMA) for the mobilization of PBSC. However, there is limited experi...

journal_title：Bone marrow transplantation

authors： Schmitt M,Xu X,Hilgendorf I,Schneider C,Borchert K,Gläser D,Freund M,Schmitt A

更新日期：2013-07-01 00:00:00

abstract：:Up to now there are no data on long-term effects of allogeneic peripheral blood cell transplantation (AlloPBPCT). In particular, long term effects on healthy donors by the mobilization procedure which includes the exposition to G-CSF over several days are unknown. Recently the possibility of an increase in risk for ac...

journal_title：Bone marrow transplantation

authors： Hasenclever D,Sextro M

更新日期：1996-03-01 00:00:00

abstract：:We examined the effects of bone marrow transplantation (BMT) on immune-mediated inner ear diseases in MRL/Mp-lpr/lpr (MRL/lpr) mice, which manifest not only lupus nephritis but also sensorineural hearing loss (SNHL) at the age of 20 weeks. These mice were treated with cyclophosphamide (CY) and irradiation (5 Gy x 2), ...

journal_title：Bone marrow transplantation

authors： Lee S,Iwai H,Sugiura K,Takeuchi K,Kushida T,Tomoda K,Inaba M,Yamashita T,Ikehara S

更新日期：2000-10-01 00:00:00

abstract：:Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

journal_title：Bone marrow transplantation

authors： Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

更新日期：2011-01-01 00:00:00

abstract：:Three patients developed abdominal pain and abnormal liver enzymes without hyperbilirubinemia, early after autografting for lymphoma. Two had received conditioning therapy with busulfan, cyclophosphamide and continuous infusion etoposide; the other had received busulfan and melphalan. Doppler ultrasound in all cases d...

journal_title：Bone marrow transplantation

authors： Grigg A,Gibson R,Bardy P,Szer J

更新日期：1996-11-01 00:00:00

abstract：:Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated fro...

journal_title：Bone marrow transplantation

authors： Yazaki M,Takahashi T,Andho M,Akatsuka Y,Ito T,Miyake Y,Ito Y,Nakamura S,Wada Y

更新日期：1999-07-01 00:00:00

abstract：:Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections predominate. Catheter-related infections and associated risk factors in 392 patients participating in a randomized adjuvant breast cancer trial and assigned to receive...

journal_title：Bone marrow transplantation

authors： Nieboer P,de Vries EG,Mulder NH,Rodenhuis S,Bontenbal M,van der Wall E,van Hoesel QG,Smit WM,Hupperets P,Voest EE,Nooij MA,Boezen HM,van der Graaf WT

更新日期：2008-10-01 00:00:00

abstract：:Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We analyzed HCT outcomes by time of transplant disease variables, including (1) blast percentage, (2) percentage of ...

journal_title：Bone marrow transplantation

authors： Trottier BJ,Sachs Z,DeFor TE,Shune L,Dolan M,Weisdorf DJ,Ustun C,Warlick ED

更新日期：2016-02-01 00:00:00

abstract：:We report the case of unusually early infection by Plasmodium vivax after autologous bone marrow transplantation in a 20-year-old female from Bangladesh affected by acute myelogenous leukemia in first complete remission (CR) who underwent autologous bone marrow transplantation in our center. During the aplastic phase ...

journal_title：Bone marrow transplantation

authors： Salutari P,Sica S,Chiusolo P,Micciulli G,Plaisant P,Nacci A,Antinori A,Leone G

更新日期：1996-10-01 00:00:00

abstract：:We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v...

journal_title：Bone marrow transplantation

authors： Thall PF,Champlin RE,Andersson BS

更新日期：2004-06-01 00:00:00

abstract：:We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transplanted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females was 3...

journal_title：Bone marrow transplantation

authors： Devergie A,Apperley JF,Labopin M,Madrigal A,Jacobsen N,Carreras E,Prentice HG,Jouet JP,Kolb HJ,Herstenstein B,Bacigalupo A,Evensen SA,Ljungman P,de Witte T,Reiffers J,Nagler A,Clark RE,Goldman JM,Gratwohl A

更新日期：1997-07-01 00:00:00

abstract：:Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, ...

journal_title：Bone marrow transplantation

authors： Rubin J,Vettenranta K,Vettenranta J,Bierings M,Abrahamsson J,Békássy AN,Håkansson Y,Frost BM,Arvidson J,Spendilow C,Winiarski J,Gustafsson B

更新日期：2011-03-01 00:00:00

abstract：:We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. The median age at HSCT was 9 (range, 2-15) years. The underlying diseases were ALL in 16 patients (5 in CR2, 3 in C...

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Sakiyama M,Nomura Y,Teranishi H,Sasaki T,Okamura J

更新日期：2011-08-01 00:00:00

abstract：:We report the cases of two severe aplastic anemia (SAA) patients who were successfully treated with syngeneic peripheral blood stem cell transplantation (PBSCT) using immunosuppression without high-dose chemotherapy or irradiation for conditioning. A 21-year-old woman with SAA of 6 years duration had been transfused h...

journal_title：Bone marrow transplantation

authors： Hwang WL,Yang Y,Chen GR,Tsai CS,Jour JH

更新日期：2000-02-01 00:00:00

abstract：:Daily administration of granulocyte colony-stimulating Factor (G-CSF) results in progenitor cell mobilization with maximum blood levels achieved after 4-7 days. In this study the short-term effects of glycosylated G-CSF at a dose of 5 microg/kg s.c. were determined so as to allow optimization of the timing of progenit...

journal_title：Bone marrow transplantation

authors： Watts MJ,Addison I,Ings SJ,Long SG,Hartley S,Warrington S,Boyce M,Linch DC

更新日期：1998-02-01 00:00:00

abstract：:During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

journal_title：Bone marrow transplantation

authors： Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

更新日期：1993-10-01 00:00:00

abstract：:This article provides a brief overview of T cell tolerance induction in the thymus, using parent----F1 bone marrow (BM) chimeras as a model. Although intrathymic tolerance is controlled largely by BM-derived cells, experiments with BM chimeras suggest that thymic epithelial cells can make a major contribution to toler...

journal_title：Bone marrow transplantation

authors： Sprent J,Kosaka H,Gao EK

更新日期：1992-01-01 00:00:00

abstract：:Data from autologous peripheral blood progenitor cell (PBPC) transplant recipients were used for cost analysis and modelling so as to link the main intervention procedures and clinical events to resource use and costs. This cohort consisted of 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years) wh...

journal_title：Bone marrow transplantation

authors： Barosi G,Marchetti M,Alessandrino P,Locatelli F,Casula S,Lunghi M,Cazzola M,Giraldi E,Bernasconi C

更新日期：1999-04-01 00:00:00

abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

journal_title：Bone marrow transplantation

authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

更新日期：2013-03-01 00:00:00